阿仑膦酸钠停药期间骨转换标志物的预测价值:PROSA研究
PROSA队列研究纳入停用阿仑膦酸钠(中位7.0年)的绝经后女性和50岁以上男性,随访2年发现骨密度显著下降、骨转换标志物在绝经前参考范围内升高,且停药3个月时p-CTX升高与髋部骨丢失相关,提示维持骨密度依赖持续抑制骨转换。
要点
- 停用阿仑膦酸钠后2年内骨密度显著下降,骨转换标志物在参考范围内升高。
- 停药3个月时p-CTX升高与12个月和24个月髋部骨丢失相关。
- 维持骨密度依赖持续抑制骨转换,p-CTX或可用于监测停药后骨丢失风险。
核心结论
- 停用阿仑膦酸钠后骨密度显著下降、骨转换标志物在参考范围内升高持续2年。
- 停药3个月时p-CTX升高与髋部骨丢失相关,提示维持骨密度依赖持续抑制骨转换。
研究设计与样本
- PROSA为在Aarhus大学医院开展的队列研究,纳入接受阿仑膦酸钠治疗≥5年、髋部骨量减少且腰椎BMD T值>-4的绝经后女性和50岁以上男性。
- 停药后于基线、1、3、6、12个月检测骨转换标志物,基线、6、12个月行DXA;扩展研究于24个月复查骨转换标志物和DXA。
- PROSA纳入136例停药者(中位用药7.0年,范围5.0-20.0年),PROSA扩展研究纳入124例。
- 主要终点为3个月或6个月p-CTX变化是否预测1年后全髋骨密度变化(Clinicaltrials.gov: NCT03051620)。
主要发现
- 24个月时腰椎骨密度下降0.74%±0.27、全髋骨密度下降2.65%±0.39、股骨颈骨密度下降2.35%±0.33、骨小梁评分下降0.97%±0.35。
- 24个月时p-CTX升高61.1%±4.7(所有p<0.05)。
- 3个月时p-CTX升高与12个月和24个月髋部骨丢失相关。
临床怎么用
- 停用阿仑膦酸钠后应监测骨密度和骨转换标志物,关注髋部骨丢失。
- 停药3个月时p-CTX升高可能提示髋部骨丢失风险增加,可考虑用于监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: In patients discontinuing ALN after a median of 7.0 years (range 5.0-20.0 years), BMD decreased, and bone turnover markers increased within the premenopausal reference range over 2 years. Increased p-CTX after 3 months was associated with greater bone loss at the hip confirming that maintenance of BMD is dependent on continued suppression of bone turnover. INTRODUCTION: It is unknown how to monitor patients discontinuing alendronate (ALN) after more than 5 years. We investigated if BTM measured before or during treatment discontinuation with ALN predict bone loss after 1 or 2 years. METHODS: PROSA was a cohort study conducted at Aarhus University Hospital including postmenopausal women and men above 50 years treated with ALN ≥ 5 years who had osteopenia at the hip and BMD T-score at the lumbar spine > - 4. ALN was discontinued and BTMs were measured at baseline, months (M) 1, 3, 6, and 12, and DXA was performed at baseline, M6, and M12. We extended the study and measured BTMs and performed DXA at M24. The primary endpoint was if changes in p-CTX at M3 or M6 predict changes in THBMD after 1 year ( Clinicaltrials.gov : NCT03051620). RESULTS: We enrolled 136 participants discontinuing ALN after a median of 7.0 years (range 5.0-20.0 years) in PROSA and 124 participants in PROSA Extension. There was a significant decrease in LSBMD - 0.74% ± 0.27, THBMD - 2.65% ± 0.39, FNBMD - 2.35% ± 0.33, and trabecular bone score - 0.97% ± 0.35 and an increase in p-CTX by 61.1% ± 4.7 (p < 0.05 for all) after 24 months. Increase in p-CTX at M3 was associated with bone loss at the hip sites at M12 and M24. CONCLUSION: In patients discontinuing ALN, BMD decreased significantly and BTMs increased within the reference range over 2 years. An increase in p-CTX after 3 months was associated with greater bone loss at the hip confirming that maintenance of BMD during treatment discontinuation is dependent on continued suppression of bone turnover.
引用
- Sølling AS, Harsløf T, Bruun NH, et al. The predictive value of bone turnover markers during discontinuation of alendronate: the PROSA study. Osteoporos Int. 2021. PMID: 33517477. doi:10.1007/s00198-021-05835-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。